Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat is an oral fixed-dose combination antiretroviral regimen marketed as **Stribild** for the treatment of HIV-1 infection. It combines two nucleoside or nucleotide reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate, with the HIV integrase strand transfer inhibitor elvitegravir and the pharmacokinetic enhancer cobicistat, which inhibits CYP3A-mediated metabolism to boost elvitegravir exposure. Developed by Gilead Sciences, the combination is used as a complete once-daily regimen, typically administered with food, for treatment-naive patients and for certain virologically suppressed patients switched from a stable regimen. All four components are small molecules, and the product does not eradicate HIV but suppresses viral replication and reduces progression to AIDS-related disease.
- Brand names
- Stribild
- Other names
- Quad pillemtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat
02
Targets
DNA polymerase alpha catalytic subunit (POLA1)CYP3A5 (Cytochrome P450 family 3 subfamily A member 5)Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)POLB (DNA polymerase beta)DNA polymerase epsilon (Pol epsilon)Integrase allosteric pocket (HIV)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat.